Pascolizumab is a
humanized monoclonal antibody for the treatment of
asthma. A Phase II
clinical trial in patients with symptomatic
glucocorticoid naive asthma has been conducted in 2001/2002.
References
Monoclonal antibodies
Experimental drugs
{{antineoplastic-drug-stub